Autres langues EXACT Therapeutics

Actions

EXTX

NO0010852213

Recherche biotechnologique et médicale

Marché Fermé - Oslo Bors Autres places de cotation 16:45:00 03/08/2026			Varia. 5j.	Varia. 1 janv.
0,8000 ^NOK	+14,29%		+20,30%	-42,03%

30/06	Exact Therapeutics se retirera d'Euronext Growth Oslo en octobre	MT
26/06	EXACT Therapeutics AS reçoit un avis de sécurité favorable pour la dose de 60 µl/kg dans le cadre de l'essai de phase 2 ENACT	RE

Autres langues

02/07	EXACT Therapeutics : Oslo Stock Exchange approves application to delist EXACT Therapeutics’ shares
30/06	Exact Therapeutics to Delist from Euronext Growth Oslo in October
30/06	EXACT Therapeutics AS - Removal from trading
26/06	EXACT Therapeutics AS Gets Positive Safety Review For 60 ?l/Kg Dose In Phase 2 ENACT Trial
26/06	EXACT Therapeutics: Positive second safety read-out from the Phase 2 ENACT trial in pancreatic cancer
26/06	EXACT Therapeutics Issues Positive Second Safety Read-Out From Phase 2 ENACT Trial In Pancreatic Cancer
17/06	Euronext Oslo Børs Receives Exact Therapeutics' Delisting Application
12/06	EXACT Therapeutics minutes from Annual General Meeting June 12, 2026
04/06	EXACT Therapeutics - webcast presentation
01/06	EXACT Therapeutics: Announces webcast regarding strategic intent to delist the company's shares from listing on Euronext Growth, Oslo
29/05	Exact Therapeutics' Board Proposes Delisting from Euronext Growth Oslo
29/05	EXACT Therapeutics - Notice for Annual General Meeting 2026
29/05	EXACT Therapeutics: Strategic intent to delist the company's shares from listing on Euronext Growth, Oslo
09/04	EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2025
09/04	EXACT Therapeutics : Annual Report 2025
26/03	EXACT Therapeutics AS: Share capital increase registered
13/03	EXACT Therapeutics AS - Minutes from extraordinary general meeting on 13 March 2026
13/03	EXACT Therapeutics : Notice of Extraordinary General Meeting for EXACT Therapeutics March 13, 2026
03/03	Exact Therapeutics as Doses First Patient in Europe in Phase 2 Enact Trial for Locally Advanced Pancreatic Cancer
03/03	EXACT Therapeutics : First patient dosed in Europe in Phase 2 trial in patients with locally advanced pancreatic cancer
03/03	EXACT Therapeutics : First patient dosed in Europe in Phase 2 trial in patients with locally advanced pancreatic cancer
27/02	EXACT Therapeutics AS: Notice of extraordinary general meeting
27/02	EXACT Therapeutics AS: Warrants exercise
11/02	EXACT Therapeutics: Investor presentation for the global investor call regarding the ongoing warrants exercise program
06/02	EXACT Therapeutics: Global investor call regarding the ongoing warrants exercise program